ETF name(Code), Benchmark Index, Inception date, creation unit, Net Asset (KRW 0.1 billion), Trustee, Rule of Dividend payment, Market Price per share (KRW), iNAV per share (KRW), trading volume (share), Total Expense ratio table
ETF Name (code)
Benchmark Index
Inception date
Creation Unit
AUM (KRW)
KB RISE HealthCare Fixed Income Balanced ETF
(253290)
FnGuide HealthCare Mix Index
2016.09.23
200,000
14,777,203,751
Trustee
Market Price per share (KRW)
NAV
Trading Volume (shares)
하나은행
12,235
※ t-1 last price
12,314
24,259
authorized participant, Liquidity provider table
Total Expense Ratio
Distribution Frequency
Year 0.35%
(Designated participating company : 0.001%,
Collective investment : 0.309%,
trust : 0.02%,
General affairs : 0.02%)
Based on the business day before the interest payment date of the stocks constituting the index in June and December (occasional payment)
The FnGuide Healthcare Balanced Index is an index consisting of stock items constituting the FnGuide Healthcare Index and three KTBs constituting the MKF 3-year KTB Index. It maintains a 7:3 ratio of bonds to stocks everyday.
Name, Ticker, Number. of shares, Weight(%), market price (KRW)
No. (Number)
Name
Ticker
Number of shares
Weight(%)
Market price (KRW)
1
KTB02625-3003(25-3)
KR103503GF38
666,666,666
27.06
666,406,666
2
KTB02875-2712(24-12)
KR103501GEC6
500,000,000
20.65
508,632,000
3
RISE HealthCare
KR7253280002
20,641
12.29
302,700,265
4
RISE KTB
KR7114100001
1,900
8.46
208,411,000
5
KTB02250-2806(25-4)
KR103501GF63
166,666,666
6.77
166,667,665
6
원화예금
KRD010010001
123,088,265
5
123,088,265
7
F 202512
KR4165WC0006
0.67
2.89
71,279,929
8
Alteogen
KR7196170005
117
2.11
51,948,000
9
Celltrion
KR7068270008
294
2.04
50,244,600
10
SAMSUNG BIOLOGICS
KR7207940008
47
1.95
47,940,000
11
Yuhan
KR7000100008
392
1.88
46,412,800
12
HLB
KR7028300002
822
1.31
32,345,700
13
LCB
KR7141080002
184
1.13
27,857,600
14
PharmaResearch
KR7214450009
48
1.09
26,832,000
15
ABL Bio
KR7298380007
237
0.88
21,685,500
16
SCD
KR7000250001
98
0.81
19,894,000
17
SKBP
KR7326030004
192
0.8
19,660,800
18
HanmiPharm
KR7128940004
44
0.62
15,356,000
19
Hugel
KR7145020004
37
0.4
9,916,000
20
HANALL BIOPHARMA
KR7009420001
248
0.35
8,556,000
21
SKBS
KR7302440003
186
0.35
8,546,700
22
ST Pharm
KR7237690003
88
0.34
8,298,400
23
Celltrionph
KR7068760008
141
0.3
7,473,000
24
CLASSYS
KR7214150005
123
0.24
5,910,150
25
L&C BIO
KR7290650001
117
0.24
5,838,300
26
SEEGENE
KR7096530001
225
0.22
5,535,000
27
GC Corp
KR7006280002
39
0.21
5,050,500
28
Hanmi Science
KR7008930000
143
0.21
5,226,650
29
Pharmicell
KR7005690003
393
0.2
4,900,710
30
HK inno.N
KR7195940002
100
0.19
4,560,000
31
MedyTox
KR7086900008
38
0.18
4,529,600
32
CHA Biotech
KR7085660009
375
0.17
4,188,750
33
DAEWOONG PHARM
KR7069620003
32
0.17
4,284,800
34
Binex
KR7053030003
202
0.13
3,284,520
35
DongKook Pharm
KR7086450004
165
0.12
3,069,000
36
ShinpoongPharm
KR7019170000
232
0.12
2,946,400
37
HLBPHARMA
KR7047920004
196
0.11
2,647,960
38
EuBio
KR7206650004
219
0.11
2,822,910
39
WONTECH
KR7336570007
302
0.11
2,748,200
40
DENTIUM
KR7145720009
46
0.1
2,488,600
41
SD Biosensor
KR7137310009
245
0.1
2,369,150
42
SELVAS AI
KR7108860008
166
0.1
2,358,860
43
BioPlus
KR7099430001
291
0.08
1,894,410
44
CUREXO
KR7060280005
204
0.08
2,060,400
45
BIONEER
KR7064550007
156
0.08
2,068,560
46
Huons Global
KR7084110006
38
0.07
1,670,100
47
T&L
KR7340570001
32
0.06
1,540,800
Investment notice
- The information provided on this website is based on reliable sources, but its accuracy and completeness are not guaranteed.
- Financial investment products are not protected by the Korea Deposit Insurance Corporation in accordance with the Depositor Protection Act, and a loss of investment principal may occur, which belongs to the investor.
- Past performance does not guarantee future profits.
- In the case of a collective investment scheme that invests in foreign securities, asset values may be lost due to risks caused by market, political, and economic conditions in the target country.
- Derivatives may lose all or a significant portion of the investment principal in a short period of time due to high price volatility, and there is a risk that the counterparty may not be able to fulfill the terms of the contract when investing in over-the-counter derivatives.
- Before investing, be sure to read the investment prospectus and contract recommendation document regarding the investment subject, redemption method, and fee.